Navigation Links
Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation
Date:12/8/2009

WASHINGTON, Dec. 8 /PRNewswire-USNewswire/ -- As part of its efforts to expand awareness of the importance of medical progress in the United States, the Pharmaceutical Research and Manufacturers of America (PhRMA) is announcing today the addition of seven new member companies.

PhRMA's Board of Directors recently voted to expand its membership to include an impressive list of progressive companies that represent some of the most innovative ideas and talent in America. With these new additions, PhRMA further bolsters its representation of a diverse group of biopharmaceutical research companies that all share the important mission of discovering and developing new medicines that can help patients win their battle against disease.

The seven new member companies will also be joining PhRMA in its support for comprehensive health care reform. America's pharmaceutical research and biotechnology companies have played a constructive role in helping ensure that a comprehensive health reform bill that is good for all Americans -- particularly one that supports medical innovation and improves patient care -- gets to President Obama's desk in the near future.

The new PhRMA members are Cubist Pharmaceuticals, Inc., Lexington, MA; OSI Pharmaceuticals, Inc., Melville, NY; Alexion Pharmaceuticals, Inc., Cheshire, CT; Ferring Pharmaceuticals, Inc., Parsippany, NJ; Talecris Biotherapeutics, Inc., Raleigh, NC; Vifor Pharma, Basking Ridge, NJ; and Xoma Ltd, Berkeley, CA. To learn more about these companies, go to www.phrma.org.

In addition to developing cutting-edge medicines that help advance patient care in the U.S. and abroad, the new members -- which have a presence in six different states -- have contributed to America's economy by supporting thousands of jobs.

Today, America continues to lead the world in the discovery and development of new medicines. In fact, more than 3 million jobs -- both direct and indirect -- have been created in the U.S. by America's pharmaceutical research and biotechnology companies. Health care reform, if done right, can help spur even more jobs, improve the quality of care for all Americans and provide a more stable foundation for future generations, according to industry officials.

"The addition of these member companies is a testament to the hard work PhRMA has been doing over the years, which has attracted enormous new talent to our ranks," said David Brennan, Chief Executive Officer, AstraZeneca and PhRMA's Chairman of the Board. "We welcome the new member companies with open arms and look forward to working with them on one of the most important issues of our lifetime -- health care reform."

Cubist President and Chief Executive Officer Michael W. Bonney said, "I am grateful to the PhRMA Board of Directors for electing me to serve among the most highly regarded leaders in our industry. Within the context of the health care reform debate and the current economic struggles and well into the future, I look forward to contributing to the dialogue surrounding our changing industry and our role in shaping that change. PhRMA members have always shown leadership on issues concerning patient care, and I am looking forward to ensuring that those issues remain paramount in the organization's mission."

"As a growing biopharmaceutical company, membership in PhRMA will enable OSI Pharmaceuticals to expand our ability to fully engage in important policy discussions at the federal, state and global level," stated Colin Goddard, Ph.D., Chief Executive Officer at OSI Pharmaceuticals, Inc. "We look forward to collaborating with other PhRMA members to ensure companies like OSI can continue to flourish in providing important life changing therapies to patients around the world."

"Advocacy organizations are operating in a very difficult environment, so we are particularly heartened to be growing our membership," says PhRMA President and CEO Billy Tauzin. "This is the result of biopharmaceutical companies -- both large and small -- seeing a tremendous opportunity to work together on important policy issues that impact patients around the world. Our primary goal is to help preserve and strengthen public policies that foster the development of new medicines -- something policymakers should consider critical if we want to develop new treatments and cures for diseases such as cancer, Parkinson's disease and heart disease."

Tauzin continued, "We are an organization committed to putting the needs of patients first. For years, PhRMA has wholeheartedly supported the notion that people do not check into the doctor's office as a Republican or Democrat, but rather as a patient. PhRMA's advocacy efforts reflect this belief and it remains to this day, a primary reason why we support public policies that encourage medical innovation in the U.S."

Today's announcement follows a recent decision by the PhRMA's Board of Directors to establish a new Committee on Small Biopharmaceutical Companies, which is composed of full and research associate members. The committee was created to address the particular issues facing these smaller specialty companies, including the impact public policies may have on such an important sector of our economy.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address: http://www.phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For more information on public health emergencies, visit http://www.rxresponse.org

For information on the danger of imported drugs, visit: http://www.buysafedrugs.info

SOURCE Pharmaceutical Research and Manufacturers of America


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
2. Seven-Year Neck Pain Study Sheds Light on Best Care
3. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
4. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
5. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
11. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... PROVIDENCE, N.J. , April 26, 2017 Phoenix ... announce its fifteenth year of fulfilling its mission of transforming ... industry is highly scrutinized, Phoenix,s innovative ... the healthcare community about the latest advances in science and ... Phoenix was founded in 2002 by ...
(Date:4/21/2017)... 21, 2017 Halo Labs announces the launch ... analysis system called the Horizon at PEGS 2017 in ... new system analyzes sub visible particulate matter in biopharmaceutical ... screening as early as candidate selection and pre-formulation. ... contract research organization Elion Labs for system ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced ... test throughout the Northeast U.S. , GlycoMark is the only clinically available ... test provides a clinically proven one- to two-week measure of hyperglycemic excursions, often ...
(Date:4/28/2017)... ... 28, 2017 , ... Children and adolescents who enter the ... children in the general population. That’s because foster care is designed to protect ... While no fault of their own, youth who have experienced trauma often have ...
(Date:4/28/2017)... ... April 28, 2017 , ... Bill Howe started his sewer and drain ... After Tina Howe joined the team, the Bill Howe brand was born and they ... rates, and giving back to the San Diego community in which they worked, lived ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/27/2017)... ... 27, 2017 , ... Today, Jefferson Health in Philadelphia and ... an agreement to create the Jane and Leonard Korman Respiratory Institute in Philadelphia. ... Korman Family Foundation. The collaboration leverages the strengths of each organization and will ...
Breaking Medicine News(10 mins):